OncoGenex Aims To Move OGX-011 Into Phase III For Hormone Refractory Prostate Cancer In Early 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm reports the investigational antisense cancer drug shows survival benefit when combined with docetaxel and prednisone.